309 related articles for article (PubMed ID: 33675056)
21. Using PET studies of P-gp function to elucidate mechanisms underlying the disposition of drugs.
Syvänen S; Hammarlund-Udenaes M
Curr Top Med Chem; 2010; 10(17):1799-809. PubMed ID: 20645912
[TBL] [Abstract][Full Text] [Related]
22. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures.
Venkatakrishnan K; Tseng E; Nelson FR; Rollema H; French JL; Kaplan IV; Horner WE; Gibbs MA
Drug Metab Dispos; 2007 Aug; 35(8):1341-9. PubMed ID: 17470526
[TBL] [Abstract][Full Text] [Related]
23. Screening novel CNS drug candidates for P-glycoprotein interactions using the cell line iP-gp: In vitro efflux ratios from iP-gp and MDCK-MDR1 monolayers compared to brain distribution data from mice.
Ozgür B; Saaby L; Janfelt C; Langthaler K; Eneberg E; Jacobsen AM; Badolo L; Montanari D; Brodin B
Eur J Pharm Biopharm; 2021 Dec; 169():211-219. PubMed ID: 34756975
[TBL] [Abstract][Full Text] [Related]
24. N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier.
Kannan P; Brimacombe KR; Zoghbi SS; Liow JS; Morse C; Taku AK; Pike VW; Halldin C; Innis RB; Gottesman MM; Hall MD
Drug Metab Dispos; 2010 Jun; 38(6):917-22. PubMed ID: 20212014
[TBL] [Abstract][Full Text] [Related]
25. Development of an
Watanabe R; Esaki T; Ohashi R; Kuroda M; Kawashima H; Komura H; Natsume-Kitatani Y; Mizuguchi K
J Med Chem; 2021 Mar; 64(5):2725-2738. PubMed ID: 33619967
[TBL] [Abstract][Full Text] [Related]
26. Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein.
Seneca N; Zoghbi SS; Liow JS; Kreisl W; Herscovitch P; Jenko K; Gladding RL; Taku A; Pike VW; Innis RB
J Nucl Med; 2009 May; 50(5):807-13. PubMed ID: 19372478
[TBL] [Abstract][Full Text] [Related]
27. [PET imaging to study the functional impact of P-glycoprotein in neuropharmacokinetics].
Marie S; Tournier N
Therapie; 2020; 75(6):623-632. PubMed ID: 32200996
[TBL] [Abstract][Full Text] [Related]
28. Utility of cerebrospinal fluid drug concentration as a surrogate for unbound brain concentration in nonhuman primates.
Nagaya Y; Nozaki Y; Kobayashi K; Takenaka O; Nakatani Y; Kusano K; Yoshimura T; Kusuhara H
Drug Metab Pharmacokinet; 2014; 29(5):419-26. PubMed ID: 24806821
[TBL] [Abstract][Full Text] [Related]
29. Comparative vulnerability of PET radioligands to partial inhibition of P-glycoprotein at the blood-brain barrier: A criterion of choice?
Breuil L; Marie S; Goutal S; Auvity S; Truillet C; Saba W; Langer O; Caillé F; Tournier N
J Cereb Blood Flow Metab; 2022 Jan; 42(1):175-185. PubMed ID: 34496661
[TBL] [Abstract][Full Text] [Related]
30. Effect of P-glycoprotein Inhibition on the Penetration of Ceftriaxone Across the Blood-Brain Barrier.
Shan Y; Cen Y; Zhang Y; Tan R; Zhao J; Nie Z; Zhang J; Yu S
Neurochem Res; 2022 Mar; 47(3):634-643. PubMed ID: 34694535
[TBL] [Abstract][Full Text] [Related]
31. Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates.
Damont A; Goutal S; Auvity S; Valette H; Kuhnast B; Saba W; Tournier N
Eur J Pharm Sci; 2016 Aug; 91():98-104. PubMed ID: 27283486
[TBL] [Abstract][Full Text] [Related]
32. [
Mairinger S; Leterrier S; Filip T; Löbsch M; Pahnke J; Hernández-Lozano I; Stanek J; Tournier N; Zeitlinger M; Hacker M; Langer O; Wanek T
J Cereb Blood Flow Metab; 2024 Jan; 44(1):142-152. PubMed ID: 37728771
[TBL] [Abstract][Full Text] [Related]
33. P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys.
Liow JS; Kreisl W; Zoghbi SS; Lazarova N; Seneca N; Gladding RL; Taku A; Herscovitch P; Pike VW; Innis RB
J Nucl Med; 2009 Jan; 50(1):108-15. PubMed ID: 19091890
[TBL] [Abstract][Full Text] [Related]
34. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540
[TBL] [Abstract][Full Text] [Related]
35. Investigation of the role and quantitative impact of breast cancer resistance protein on drug distribution into brain and CSF in rats.
Katagiri Y; Kawaguchi H; Umemura K; Tadano J; Miyawaki I; Takano M
Drug Metab Pharmacokinet; 2022 Feb; 42():100430. PubMed ID: 34896751
[TBL] [Abstract][Full Text] [Related]
36. Assessing extent of brain penetration in vivo (K
Langthaler K; Jones CR; Brodin B; Bundgaard C
Eur J Pharm Sci; 2023 Nov; 190():106554. PubMed ID: 37543065
[TBL] [Abstract][Full Text] [Related]
37. The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid.
Westerhout J; Smeets J; Danhof M; de Lange EC
J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):327-42. PubMed ID: 23539188
[TBL] [Abstract][Full Text] [Related]
38. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios.
Kalvass JC; Maurer TS; Pollack GM
Drug Metab Dispos; 2007 Apr; 35(4):660-6. PubMed ID: 17237155
[TBL] [Abstract][Full Text] [Related]
39. Experimental and Computational Methods to Assess Central Nervous System Penetration of Small Molecules.
Gupta M; Feng J; Bhisetti G
Molecules; 2024 Mar; 29(6):. PubMed ID: 38542901
[TBL] [Abstract][Full Text] [Related]
40. Use of cassette dosing approach to examine the effects of P-glycoprotein on the brain and cerebrospinal fluid concentrations in wild-type and P-glycoprotein knockout rats.
Liu X; Cheong J; Ding X; Deshmukh G
Drug Metab Dispos; 2014 Apr; 42(4):482-91. PubMed ID: 24398459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]